A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from day one
- Coverage possible with two-week gap before early delivery
- Vaccination in the third trimester still offers significant protection for infants
Compelling evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month timeframe, providing robust and representative information of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scope of this study offers healthcare professionals and prospective parents with trust in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results paint a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference emphasises the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospitalisations. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology captured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when administered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed properly. Parents frequently observe their babies fighting for breath, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most newborns improve through supportive care, a limited though important group succumb from respiratory syncytial virus complications annually, making prevention through vaccination a critical public health imperative for defending the most vulnerable and youngest members of society.
- RSV triggers lung inflammation, causing serious respiratory problems in infants
- Half of all newborns contract the infection in their first few months of life
- Symptoms range from mild colds to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies need serious hospital treatment for RSV each year
- A small number of babies die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women getting their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The messaging from health authorities remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows robust and reliable protection irrespective of geographical location.
- NHS trusts deploying multiple messaging strategies to reach pregnant women
- Geographic variations in immunisation take-up in different parts of England require targeted improvement
- Local healthcare systems modifying schemes to meet local requirements and situations
Practical implications and parent viewpoints
The vaccine’s outstanding effectiveness delivers real advantages for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this preventative solution, the 80% decrease in admissions equates to thousands of infants shielded from serious illness. Parents no more face the troubling prospect of seeing their babies gasping for air or struggle to eat, symptoms that mark serious RSV disease. The vaccine has fundamentally shifted the picture of neonatal breathing health, providing expectant mothers a active means to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to profound brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab underscores the profound consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to pregnant women during their late pregnancy, converting what was once an inevitable seasonal threat into a manageable health risk.